Clinical Trial Update: A 4 Week Study to Investigate the Safety and Tolerability of AZD5069 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) [Phase 2]

View source ↗

Summary

Phase 2 study completed evaluating the safety and tolerability of AZD5069 in patients with moderate-to-severe chronic obstructive pulmonary disease. Results wer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchitis
• Chronic Obstructive Pulmonary Disease
• Emphysema

Drugs mentioned

• AZD5069 (CXCR2 inhibitor)

Snippet

Sponsor: AstraZeneca | Conditions: Scientific Terminology Chronic Obstructive Pulmonary Disease (COPD), Laymen Terminology Chronic Bronchitis and Emphysema | Phase 2 | Status: COMPLETED | Results posted: 2015-05-19